-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
YM-53601 free base
![{PARAM:[Name]}({[CAS]})](https://resource.bocsci.com/structure/182959-28-0.gif)
| Category | Hepatitis C Virus (HCV) |
| CAS | 182959-28-0 |
| Description | YM-53601 free base is a squalene synthase inhibitor with an IC50 of 79 nM for human hepatoma cells. It is a lipid lowering agent that can reduce plasma cholesterol and triglyceride levels in vivo. It is also an inhibitor of farnesyl-diphosphate farnesyltransferase 1 (FDFT1) enzyme activity and can inhibit the proliferation of HCV. |
Product Information
| Synonyms | (E)-3-[2-(carbazol-2-yloxy)-1-fluoroethylidene]quinuclidine; 2-[2-Fluoro-2-[(3E)-quinuclidine-3-ylidene]ethoxy]-9H-carbazole; 9H-Carbazole, 2-[2-(1-azabicyclo[2.2.2]oct-3-ylidene)-2-fluoroethoxy]-, (E)- |
| IUPAC Name | 2-[(2E)-2-(1-azabicyclo[2.2.2]octan-3-ylidene)-2-fluoroethoxy]-9H-carbazole |
| Molecular Weight | 336.40 |
| Molecular Formula | C21H21FN2O |
| Canonical SMILES | C1CN2CCC1C(=C(COC3=CC4=C(C=C3)C5=CC=CC=C5N4)F)C2 |
| InChI | InChI=1S/C21H21FN2O/c22-19(18-12-24-9-7-14(18)8-10-24)13-25-15-5-6-17-16-3-1-2-4-20(16)23-21(17)11-15/h1-6,11,14,23H,7-10,12-13H2/b19-18- |
| InChIKey | XNDCPFTULXRWQH-HNENSFHCSA-N |
| Boiling Point | 541.2±40.0°C (Predicted) |
| Flash Point | 281.1±27.3 °C |
| Purity | ≥95% |
| Density | 1.30±0.1 g/cm3 (Predicted) |
| Solubility | Soluble in DMSO |
| Appearance | Solid powder |
| Storage | Store at -20°C |
| Animal Admin | Rats are given a single oral administration of YM-53601 at the concentration of 50 mg/kg, followed 1 h later by intraperitoneal injection of [14C] acetate (40.5 μCi per animal). The rats and the hamsters are anaesthetized with diethyl ether and killed 1 h after the [14C]-acetate injection. Cholesterol biosynthesis is assayed. |
| Complexity | 528 |
| Exact Mass | 336.16379146 |
| Index Of Refraction | 1.689 |
| In Vivo | YM-53601 inhibits cholesterol biosynthesis from acetate in a dose-dependent manner in the plasma of rats. At the same time, YM-53601 inhibits both FFA and triglyceride biosynthesis in rats treated with cholestyramine over the same dose range at which it inhibits cholesterol biosynthesis. YM-53601 by single oral administration decreases the enhanced plasma triglyceride levels in hamsters induced by an injection of protamine sulfate, which inhibits lipoprotein lipase (LPL) and consequently increases plasma very low-density lipoprotein (VLDL) triglyceride levels. YM-53601 also decreases the enhanced plasma triglyceride and cholesterol levels in hamsters treated with Triton WR1339, which also inhibits the degradation of VLDL. Plasma cholesterol was significantly decreased as soon as 1 h after single administration of YM-53601 in hamsters fed a normal diet. |
| Target | Farnesyl Transferase; HCV |
| Vapor Pressure | 0.0±1.4 mmHg at 25°C |
| XLogP3-AA | 3.5 |